← Back to Search

Procedure

PVI, non-PV triggers for Atrial Fibrillation (PRECAF Trial)

N/A
Waitlist Available
Led By Saman Nazarian, M.D., Ph.D
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with paroxysmal or persistent atrial fibrillation; AND Undergoing first AF ablation; AND Age ≥ 18 years.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time to af recurrence will be recorded as time to the first ecg or monitor that shows af recurrence between the end of the blanking period (90 days post ablation) and the end of the study (180 days post ablation).
Awards & highlights

PRECAF Trial Summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting millions of people in the US and around the world. Over the last 20 years, catheter based AF ablation has been widely adopted offering improved symptom control for many patients worldwide. However, long-term success rates remain suboptimal. Prior work indicates that distal connections between coronary sinus musculature and the left atrium exist and provide a substrate for single or multiple reentry beats as a trigger for atrial fibrillation. In this trial, the investigators will examine the efficacy of elimination of distal connection(s) between coronary sinus and left atrial musculature for suppression of recurrent atrial arrhythmias.

Eligible Conditions
  • Atrial Fibrillation
  • Cardiac Arrhythmias

PRECAF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PRECAF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time to af recurrence will be recorded as time to the first ecg or monitor that shows af recurrence between the end of the blanking period (90 days post ablation) and the end of the study (180 days post ablation).
This trial's timeline: 3 weeks for screening, Varies for treatment, and time to af recurrence will be recorded as time to the first ecg or monitor that shows af recurrence between the end of the blanking period (90 days post ablation) and the end of the study (180 days post ablation). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to recurrence of atrial arrhythmias
Secondary outcome measures
Atrial fibrillation burden

PRECAF Trial Design

2Treatment groups
Active Control
Group I: PVI, non-PV triggersActive Control1 Intervention
Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
Group II: PVI, non-PV triggers & CS-LA connectionActive Control2 Interventions
Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,992 Previous Clinical Trials
42,875,300 Total Patients Enrolled
16 Trials studying Atrial Fibrillation
2,731 Patients Enrolled for Atrial Fibrillation
Saman Nazarian, M.D., Ph.DPrincipal InvestigatorUniversity of Pennsylvania

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~15 spots leftby Mar 2025